BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses growth accelerates
Q3 FY2026 operating expenses of $901.31B rose 131913.8% year over year, ahead of the +47406.7% change in trailing-twelve-month operating expenses. Sequentially, it rose 133233.4% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.
Context
- Operating expenses amounted to 60.6% of revenue in FY2025, down 2.1 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +131913.8% holds above the trailing-twelve-month pace of +47406.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 1.95B USD
- Year-over-year change
- +9.0%
- 4-year CAGR
- +7.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.95B | +9.0% |
| FY2024 | 2024-12-31 | 1.79B | +5.2% |
| FY2023 | 2023-12-31 | 1.7B | +18.8% |
| FY2022 | 2022-12-31 | 1.43B | -1.8% |
| FY2021 | 2021-12-31 | 1.46B | — |
Operating Expenses vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +47406.7% is the highest of 11, against a peer median of +22.9%.
- Operating expenses amounts to 87.9% of revenue for BMRN, versus a peer median of 98.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $902.93B USD | +47406.7% | +10.9% | 87.9% | |
| LTM Sep 2026 | $6.72B USD | +9.7% | +15.8% | 51.7% | |
| LTM Jun 2026 | $2.83B USD | +26.4% | +15.3% | 58.9% | |
| LTM Jun 2026 | $1.76B USD | +35.1% | +36.8% | 155.1% | |
| LTM Sep 2026 | $1.51B USD | +22.3% | +10.0% | 157.1% | |
| LTM Jun 2026 | $1.21B USD | +36.9% | +21.2% | 169.6% | |
| LTM Mar 2026 | $1.12B USD | +10.3% | +3.8% | 167.5% | |
| LTM Sep 2026 | €872.49M EUR | +23.4% | +6.2% | 72.2% | |
| LTM Sep 2026 | $753.04M USD | +45.8% | +8.5% | 115.7% | |
| LTM Jun 2026 | $712.31M USD | -28.4% | -10.0% | 70.6% | |
| LTM Mar 2026 | $299.02M USD | +4.7% | +22.2% | 81.0% | |
| Peer median (excluding BMRN) | — | +22.9% | +12.7% | 98.3% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.